Redcare Pharmacy stock: Q3 growth and 15 million customers

Redcare Pharmacy reported a strong third quarter on October 29, with group revenue rising 18% year over year to 847 million euros. The company also confirmed its upgraded 2026 targets, while prescription sales in Germany remained the main growth engine.

The Redcare Pharmacy investor release said prescription revenue increased 31% to 358 million euros in the third quarter. German prescription revenue advanced 56% to 197 million euros. Adjusted EBITDA rose 68% to 28.7 million euros, lifting the margin to 3.4% from 2.4% a year earlier.

Customer base crosses 15 million

On November 5, Financial Times company announcements carried Redcare Pharmacy's announcement that more than 15 million people across Europe were active customers. The company defines an active customer as someone who placed at least one order in the previous twelve months. The repeat-order rate exceeded 90% in the third quarter.

Redcare Pharmacy said its active customer base reached 15.2 million at the end of September, up 1.5 million from a year earlier. The company operates in seven European markets, with Germany's electronic prescription business supporting the prescription growth described in the quarterly release.

Share price remains below Thursday's close

Redcare Pharmacy stock traded at 71.10 euros on Lang & Schwarz at 23:00 CET on Friday, November 6, 0.78 percent above the Xetra close of Friday. The latest quote remained below Thursday's 72.50-euro close, leaving the stock sensitive to how investors weigh prescription momentum against the company's still modest profitability.

Investors can follow the real-time quote of Redcare Pharmacy stock.

The broader Dutch market can be followed through the AEX Index.

Redcare Pharmacy's next scheduled publication is the fiscal 2026 trading update on January 11, 2027. More news and analyses on Redcare Pharmacy stock remain available in the company topic.